{"meshTagsMajor":["Aromatase Inhibitors"],"meshTags":["Aminoglutethimide","Antineoplastic Agents, Hormonal","Aromatase","Aromatase Inhibitors","Breast Neoplasms","Chemotherapy, Adjuvant","Enzyme Inhibitors","Estrogens","Female","Humans","Neoplasms, Hormone-Dependent","Postmenopause","Tamoxifen"],"meshMinor":["Aminoglutethimide","Antineoplastic Agents, Hormonal","Aromatase","Breast Neoplasms","Chemotherapy, Adjuvant","Enzyme Inhibitors","Estrogens","Female","Humans","Neoplasms, Hormone-Dependent","Postmenopause","Tamoxifen"],"genes":["Aromatase","aromatase"],"organisms":["9606"],"publicationTypes":["Journal Article","Review"],"abstract":"The aromatase inhibitors are established first-line drugs for treating metastatic breast cancer in postmenopausal women, and are gaining acceptance as adjuvant treatment as well.","title":"Aromatase inhibitors in breast cancer: current and evolving roles.","pubmedId":"12109640"}